In total, 140 out of 146 samples (96%) of adenocarcinoma were adequate for ALK, ROS1 and TPS PD‐L1 immunohistochemical assessment, and 137/146 (93.8%) were adequate for molecular profiling. The gene discussed is ALK; the disease is adenocarcinoma.